.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Sentio bone-conduction implant offers a promising solution for individuals suffering from conductive or mixed hearing loss. Specifically, this active transcutaneous system received approval in 2024 and targets patients who cannot benefit from traditional hearing aids. Clinicians recently analyzed its initial performance to establish efficacy and safety benchmarks.
Notably, the study results revealed substantial improvements in hearing sensitivity. For instance, the mean hearing threshold improved significantly from 56.3 dB HL (unaided) to 25.3 dB HL post-activation. Consequently, this gain outperformed outcomes previously achieved with softband solutions. Furthermore, speech recognition testing in free field conditions showed marked progress. Patients also reported significant subjective benefits, as evidenced by improved Abbreviated Profile of Hearing Aid Benefit (APHAB) scores. Therefore, the device effectively addresses the core communication challenges faced by this patient population.
Moreover, the surgical procedure demonstrated a high safety profile. Researchers reported that all initial surgeries were completed without complications. However, one patient did require a revision surgery, which surgeons performed successfully. Aside from this single event, no other adverse outcomes occurred. In addition, the hearing thresholds remained remarkably stable during the one-month follow-up period. Because the system utilizes a transcutaneous design, it avoids many of the skin-related complications common with percutaneous implants.
The Sentio system provides significant improvements in hearing thresholds and speech recognition. Clinical data shows an average threshold improvement from 56.3 dB HL to 25.3 dB HL, alongside high patient satisfaction rates.
Yes, the implant demonstrates a strong safety profile. Most surgeries are completed without complications, and the transcutaneous design minimizes the risk of long-term skin-related issues typically associated with older bone-conduction technologies.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Cywka KB et al. Sentio Bone-Conduction Implant: Early Outcomes in Patients With Conductive or Mixed Hearing Loss. Laryngoscope. 2026 Jun 22. doi: 10.1002/lary.70704. PMID: 42332362.
Hol MKS et al. A Prospective, Multicenter Clinical Investigation on the Safety and Performance of a New Active Transcutaneous Bone-Anchored Implant System. Otol Neurotol. 2026;47(1):15-22.
Oticon Medical. Sentio System: Technical Specifications and Clinical Indications. 2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Sentio bone-conduction implant demonstrates significant hearing improvements and high safety for conductive or mixed hearing loss. Early 2026 data shows mean thresholds improving from 56.3 to 25.3 dB HL with high patient satisfaction and minimal surgical complications.
2 months ago
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
Last week
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
4 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
4 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
Last week
